Contributions
Abstract: EP1330
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Introduction: Multiple Sclerosis (MS) frequently causes cognitive impairment aside from somatic symptoms, its prevalence ranging from 43-70%. Despite its frequency, there is very little data on its incidence, and none, utilizing the BICAMS screening battery.
The aim of our study was to determine the incidence of cognitive impairment among patients with relapsing-remitting (R-R) MS and clinically isolated syndrome (CIS) and assess possible predicting factors.
Patients and methods: We followed-up 242 R-R MS and CIS patients after 1 year, treated at the Department of Neurology of the University of Szeged and at the Jahn Ferenc Dél-Pest Hospital of Budapest from the originally recruited 553 patients. We used the BICAMS battery to assess their cognitive state. For statistical analysis, we used logistic regression analysis, Chi-square and Fisher exact tests. We calculated the incidence rate.
Results: The mean age of our patients was 45.5±11.3 years, the mean age at disease onset was 31.3±9.8 years, the mean disease duration was 15.2±7.6 years and the median EDSS score was 2 points (range:0-6.0). Of the 243 patients, 62 were men and 180 women (man-women ratio was 1:2.9).
At baseline, 110 of the 242 patients were cognitively preserved. At the time of the follow-up, 25 patients developed some level of cognitive impairment (22.7%), the incidence rate was 103/1000 person-years. We found no significant predictor of developing CI with regression analysis. There was no significant difference between the genders, yet the proportion of male patients was higher (31% against 21%; p>0.05).
Discussion: At a 1 year follow-up, we found the incidence of cognitive impairment to be 103/1000 person-years among our patient group, which is in accordance to a previous report from Italy after a longer follow-up. We found no significant difference between the genders (unlike in our prevalence investigation), yet the proportions were slightly higher among males, so the lack of significance may be due to the relatively low number of male patients. We found no significant predictor of developing CI in this short follow-up period.
Disclosure:
Dániel Sandi: nothing to disclose.
Tamás Biernacki: nothing to disclose.
Zsanett Fricska-Nagy: nothing to disclose.
Dóra Szekeres: nothing to disclose.
Judit Füvesi: nothing to disclose.
Zsigmond Tamás Kincses: nothing to disclose.
Csilla Rózsa: nothing to disclose.
Krisztián Kása: nothing to disclose.
Judit Matolcsi: nothing to disclose.
Dóra Zboznovits: nothing to disclose.
Zita Burány: nothing to disclose.
Éva Langane: nothing to disclose.
László Vécsei: nothing to disclose.
Krisztina Bencsik: nothing to disclose.
Abstract: EP1330
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Introduction: Multiple Sclerosis (MS) frequently causes cognitive impairment aside from somatic symptoms, its prevalence ranging from 43-70%. Despite its frequency, there is very little data on its incidence, and none, utilizing the BICAMS screening battery.
The aim of our study was to determine the incidence of cognitive impairment among patients with relapsing-remitting (R-R) MS and clinically isolated syndrome (CIS) and assess possible predicting factors.
Patients and methods: We followed-up 242 R-R MS and CIS patients after 1 year, treated at the Department of Neurology of the University of Szeged and at the Jahn Ferenc Dél-Pest Hospital of Budapest from the originally recruited 553 patients. We used the BICAMS battery to assess their cognitive state. For statistical analysis, we used logistic regression analysis, Chi-square and Fisher exact tests. We calculated the incidence rate.
Results: The mean age of our patients was 45.5±11.3 years, the mean age at disease onset was 31.3±9.8 years, the mean disease duration was 15.2±7.6 years and the median EDSS score was 2 points (range:0-6.0). Of the 243 patients, 62 were men and 180 women (man-women ratio was 1:2.9).
At baseline, 110 of the 242 patients were cognitively preserved. At the time of the follow-up, 25 patients developed some level of cognitive impairment (22.7%), the incidence rate was 103/1000 person-years. We found no significant predictor of developing CI with regression analysis. There was no significant difference between the genders, yet the proportion of male patients was higher (31% against 21%; p>0.05).
Discussion: At a 1 year follow-up, we found the incidence of cognitive impairment to be 103/1000 person-years among our patient group, which is in accordance to a previous report from Italy after a longer follow-up. We found no significant difference between the genders (unlike in our prevalence investigation), yet the proportions were slightly higher among males, so the lack of significance may be due to the relatively low number of male patients. We found no significant predictor of developing CI in this short follow-up period.
Disclosure:
Dániel Sandi: nothing to disclose.
Tamás Biernacki: nothing to disclose.
Zsanett Fricska-Nagy: nothing to disclose.
Dóra Szekeres: nothing to disclose.
Judit Füvesi: nothing to disclose.
Zsigmond Tamás Kincses: nothing to disclose.
Csilla Rózsa: nothing to disclose.
Krisztián Kása: nothing to disclose.
Judit Matolcsi: nothing to disclose.
Dóra Zboznovits: nothing to disclose.
Zita Burány: nothing to disclose.
Éva Langane: nothing to disclose.
László Vécsei: nothing to disclose.
Krisztina Bencsik: nothing to disclose.